DIMINAPIT

Indications

• Acute pain management
• Chronic pain conditions
• Osteoarthritis
• Rheumatoid arthritis
• Post-operative pain

Dosage

Children: Refer to BNF for Children for appropriate paediatric dosing guidelines.

Adults: Refer to BNF for appropriate adult dosing guidelines.

Mechanism of action

Aceturate acts as an analgesic and anti-inflammatory agent. Its mechanism involves the inhibition of the cyclooxygenase (COX) enzymes, leading to a decrease in the synthesis of prostaglandins, which are mediators of pain and inflammation. This results in reduced pain perception and inflammation at the site of action.

Pharmacodynamics

Aceturate exhibits dose-dependent analgesic effects, providing relief from mild to moderate pain. Its anti-inflammatory properties help to reduce swelling and discomfort in conditions like arthritis and musculoskeletal disorders. The onset of action is typically rapid, leading to quick relief of symptoms.

Pharmacokinetics

Aceturate is absorbed after oral administration, with peak plasma concentrations reached within a few hours. It undergoes hepatic metabolism and is excreted primarily via the renal route. The elimination half-life can vary based on individual metabolic factors but is generally within a manageable range for regular dosing.

Pregnancy

No adequate studies are available on the use of aceturate in pregnant women. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when aceturate is administered to breastfeeding mothers. The excretion of aceturate in human milk is unknown.

Storage

Store at room temperature, away from moisture and heat. Protect from light.

Indications

• Pain relief
• Fever reduction
• Assessment of drug metabolism

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations for adults.

Mechanism of action

Antipyrine acts primarily in the central nervous system (CNS) by increasing the pain threshold. It achieves this by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3, which are enzymes involved in the synthesis of prostaglandins (PGs).

Pharmacodynamics

As an analgesic and antipyretic, antipyrine effectively reduces pain and fever. It is administered orally and via ear drops, and is frequently used in clinical settings to evaluate the effects of various drugs or diseases on hepatic drug-metabolizing enzymes.

Pharmacokinetics

Antipyrine is well absorbed from the gastrointestinal tract and undergoes extensive hepatic metabolism. Its elimination half-life varies, influenced by hepatic function and other factors. The drug is primarily excreted in urine as metabolites.

Adverse effects

• Nausea
• Vomiting
• Rash
• Dizziness
• Headache

Precautions

• Use with caution in patients with liver impairment
• Monitor for signs of allergic reactions
• Consider potential interactions with other medications affecting liver enzymes

Pregnancy

Antipyrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administered to breastfeeding mothers due to the lack of data on excretion in human milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Ear drops

Indications

• Trypanosomiasis (sleeping sickness)
• Nagana in livestock
• Infections caused by Trypanosoma brucei
• Infections caused by Trypanosoma congolense

Dosage

Children: Paediatric dosing of diminazene should be derived from the BNF for Children, taking into account the weight and age of the child. Refer to the BNF for Children for specific dosing recommendations.

Adults: The dosage for adults should be determined based on the specific condition and patient factors. Refer to the BNF for accurate dosing guidelines.

Mechanism of action

Diminazene acts by inhibiting the enzyme dihydrofolate reductase, which is crucial for the synthesis of folate in protozoa. This inhibition disrupts the folate metabolic pathway, leading to a decrease in nucleic acid synthesis and ultimately resulting in the death of the protozoan parasites. Additionally, it may interfere with the mitochondrial function of the parasites, further contributing to its antiparasitic effects.

Pharmacodynamics

The pharmacodynamics of diminazene involve its selective action on trypanosomes, with the drug being less toxic to host cells. It has a high affinity for the target enzyme, allowing for effective suppression of protozoan growth. The drug's therapeutic index is favorable, meaning it can effectively treat infections at doses that are relatively safe for the host.

Pharmacokinetics

Diminazene is well-absorbed following parenteral administration. It is widely distributed throughout the body, with a significant volume of distribution. The drug undergoes hepatic metabolism, and its elimination half-life can vary depending on species and individual health. Excretion is primarily via the urine, with metabolites detected in both urine and feces.

Adverse effects

• Anorexia
• Vomiting
• Diarrhoea
• Lethargy
• Neurological signs (e.g., tremors, ataxia)
• Hypersensitivity reactions

Precautions

• Use with caution in animals with hepatic or renal impairment.
• Monitor for signs of toxicity, especially in cases of overdose.

Pregnancy

Safety during pregnancy has not been established; use only if the benefits outweigh the risks.

Breast-feeding

Safety during breastfeeding has not been established; use with caution.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Injection solution

Mechanism of action

Antipyrine is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis.

Pharmacodynamics

Antipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)